BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Vertex Secures Three Phase III Wins for Non-Opioid Pain Candidate, Plans NDA

  After VX-548 demonstrated significant pain relief in surgical and non-surgical settings, Vertex Pharmaceuticals is preparing to file a New Drug Application for the non-opioid candidate by mid-2024.

  January 30, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Sarepta Touts Positive Phase II Results for Next-Gen DMD Treatment

  Gene therapy company Sarepta Therapeutics provided additional data for SRP-5051 in treating Duchenne muscular dystrophy patients who are amenable to exon 51 skipping.

  January 30, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Business

  Gilead Expands Arcus Collaboration with $320M Equity Investment

  Gilead Sciences and Arcus Biosciences have amended their collaboration agreement in an effort to accelerate an anti-TIGIT program, the companies announced Monday.

  January 30, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Career Advice

  Psychometric Testing in Pharma and Biotech Hiring

  A minority of companies in the industry use personality tests in hiring. Here’s why—and how to approach the assessments.

  January 30, 2024

   · 

  4 min read

   · 

  Sunitha Chari
• 

  Business

  How a Promise Sparked Ray CEO Paul Bresge’s Quest to Treat a Blinding Disease

  After Tamar Bresge was diagnosed with retinitis pigmentosa at age 15, her entrepreneurial father made it his mission to help find a cure.

  January 30, 2024

   · 

  4 min read

   · 

  Mollie Barnes
• 

  Policy

  Analysts Expect CMS to Ask for Steep Drug Discounts in Initial IRA Proposal: Reuters

  The Centers for Medicare and Medicaid Services’ initial proposed drug price cuts, due to pharma companies by Thursday under the Inflation Reduction Act, could range from 25% to 60%, analysts told Reuters.

  January 30, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  High Costs of GLP-1 Drugs Fuel Debate

  Stringent regulation, manufacturing costs and absence of price control contribute to high GLP-1 agonist costs in the U.S. Patients could go to other countries for cheaper treatment.

  January 30, 2024

   · 

  4 min read

   · 

  Patience Asanga
• 

  Business

  Pfizer Gets Q4 Earnings Beat on Smaller Than Expected COVID-19 Sales Decline

  Excluding its COVID-19-products Comirnaty and Paxlovid, Pfizer’s revenue in the fourth quarter of 2023 grew 8%. The company projects full-year revenue in 2024 to remain about flat.

  January 30, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Policy

  AstraZeneca, Daiichi’s Enhertu Given FDA Priority Review for Metastatic HER2 Positive Solid Tumors

  The FDA has granted Priority Review for AstraZeneca and Daiichi Sankyo’s supplemental BLA for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumors.

  January 30, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Drug Development

  Shortage of GLP-1 RAs Tied to Rise in Counterfeit Products: WHO

  The persistent shortage of genuine glucagon-like peptide 1 receptor agonist products has led to an increase in fake versions, the World Health Organization warned on Monday.

  January 30, 2024

   · 

  2 min read

   · 

  Tristan Manalac